OncoMatch/Clinical Trials/NCT05913804

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Is NCT05913804 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies YTS104 Cells for relapsed or refractory multiple myeloma.

Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT05913804Data as of May 2026

Treatment: YTS104 Cells — This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 3 prior lines

Must have received: proteasome inhibitor

Must have received: immunomodulator

Cannot have received: car-t cell therapy

Exception: undetectable car-t cells or car-t cells below the lower limit of detection

Lab requirements

Blood counts

Good organ function

Kidney function

Good organ function

Liver function

Good organ function

Good organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify